BioNxt Solutions Inc. Expands Patent Portfolio for Sublingual Delivery Technologies
Vancouver, BC / ACCESSWIRE / December 19, 2024
BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the expansion of its intellectual property portfolio with the filing of new international patents for sublingual delivery technologies targeting autoimmune neurodegenerative diseases. Building upon the positive International Preliminary Report on Patentability (IPRP) issued by the European Patent Office (EPO) in September 2024, BioNxt has initiated national-level filings in key jurisdictions, including the United States, Canada, Europe, and Japan.
Sublingual drug delivery is a method of administering medication through the mucous membranes under the tongue. This route of administration allows for rapid absorption of drugs into the bloodstream, bypassing the digestive system and potentially enhancing their efficacy. BioNxt’s innovative sublingual delivery technologies have shown promise in targeting autoimmune neurodegenerative diseases, which are complex conditions with limited treatment options.
By expanding its patent portfolio internationally, BioNxt is positioning itself as a leader in the development of novel drug delivery systems for challenging medical conditions. The company’s focus on autoimmune neurodegenerative diseases highlights its commitment to addressing unmet medical needs and improving patient outcomes.
Impact on Individuals
Individuals living with autoimmune neurodegenerative diseases may benefit from BioNxt’s innovative sublingual delivery technologies, which have the potential to offer more effective treatment options. By targeting these complex conditions with specialized drug delivery systems, BioNxt is paving the way for advancements in personalized medicine and improved quality of life for patients.
Global Impact
The expansion of BioNxt’s intellectual property portfolio for sublingual delivery technologies signals progress in the field of drug delivery and precision medicine. By filing new international patents and securing protection for its innovative approaches, BioNxt is contributing to the global efforts to advance healthcare solutions for challenging diseases. This development underscores the importance of ongoing research and innovation in the biotechnology sector.
Conclusion
In conclusion, BioNxt Solutions Inc.’s expansion of its patent portfolio for sublingual delivery technologies represents a significant milestone in the company’s efforts to drive innovation in drug delivery and address unmet medical needs. By focusing on autoimmune neurodegenerative diseases and pursuing international patent protection, BioNxt is demonstrating its commitment to advancing healthcare solutions and improving patient care on a global scale.
